1-羟基-1-(6-苯基甲氧基-1,2,3,4-四氢萘-1-基)脲 | 139148-95-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 1-羟基-1-(6-苯基甲氧基-1,2,3,4-四氢萘-1-基)脲
• 英文名称: (+/-)-N-hydroxy-N-[1,2,3,4-tetrahydro-6-(benzyloxy)-1-naphthalenyl]urea
• 英文别名: N-Hydroxy-N-(1,2,3,4-tetrahydro-6-(phenylmethoxy)-1-naphthalenyl)urea；1-hydroxy-1-(6-phenylmethoxy-1,2,3,4-tetrahydronaphthalen-1-yl)urea
• CAS: 139148-95-1；139149-52-3；139149-53-4
• 化学式: C₁₈H₂₀N₂O₃
• 分子量: 312.368
• InChiKey: HGXVXGSOOPCMHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  75.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-4-benzyloxazolidin-2-one-3-carbonyl chloride 、 1-羟基-1-(6-苯基甲氧基-1,2,3,4-四氢萘-1-基)脲 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 、
  参考文献：
  名称：

  Resolution of hydroxyureas

  摘要：

  Racemic hydroxyureas can be efficiently resolved on a preparative scale using (4S)-4-benzyl-2-oxazolidinone-3-carbonyl chloride 3. The resulting carbamates can be separated by chromatography and hydrolysis of these diastereomers yields enantiomerically pure hydroxyureas.

  DOI：

  10.1016/s0040-4039(00)73875-5
• 作为产物：
  描述：

  6-Benzyloxy-3,4-dihydro-2H-naphthalen-1-one oxime 在 盐酸 、 吡啶硼烷 作用下， 以 四氢呋喃 为溶剂， 生成 1-羟基-1-(6-苯基甲氧基-1,2,3,4-四氢萘-1-基)脲
  参考文献：
  名称：

  Bicyclic N-Hydroxyurea Inhibitors of 5-Lipoxygenase:  Pharmacodynamic, Pharmacokinetic, and in Vitro Metabolic Studies Characterizing N-Hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea

  摘要：

  A series of N-hydroxyurea derivatives have been prepared and examined as inhibitors of 5-lipoxygenase. Oral activity was established by examining the inhibition of LTB(4) biosynthesis in an ex vivo assay in the mouse. The pharmacodynamic performance in the mouse of selected compounds was assessed using an ex vivo LTB(4) assay and an adoptive peritoneal anaphylaxis assay at extended pretreat times. Compounds with an extended duration of action were reexamined as the individual enantiomers in the ex vivo assay, and the (S) enantiomer of N-hydroxy-N-[2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl]urea, (+)-1a (SE 202235), was selected as the compound with the best overall profile. Higher plasma concentrations and longer plasma half-lives were found for (+)-1a relative to its enantiomer in the mouse, monkey, and dog. In vitro metabolic studies in mouse liver microsomes established enantiospecific glucuronidation as a likely mechanism for the observed differences between the enantiomers of la. Enantioselective glucuronidation favoring (-)-1a was also found in human liver microsomes.

  DOI：

  10.1021/jm960271d

文献信息

• 5-LIPOXYGENASE INHIBITORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0522000A1

  公开（公告）日：1993-01-13
• Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas
  申请人：Claesson Hans-Erik

  公开号：US20080081835A1

  公开（公告）日：2008-04-03

  The invention relates to the use of an inhibitor of the biosynthesis and/or function of LTB 4 for the manufacture of a medicament for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), B-prolymphocytic leukemia (B-PLL) or B-cell lymphoma. Preferably, the inhibitor of the biosynthesis and/or function of LTB 4 is the inhibitor of 5-LO BWA4C or the inhibitor of FLAP MK-886.
• Method and composition for treating inflammatory disorders
  申请人：Pereswetoff-Morath Lena

  公开号：US20090220583A1

  公开（公告）日：2009-09-03

  There is provided homogeneous pharmaceutical compositions for the treatment of inflammatory disorders comprising an antiinflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier.
• Method and Composition for Treating Inflammatory Disorders
  申请人：Meda AB

  公开号：US20160166508A1

  公开（公告）日：2016-06-16

  There is provided homogeneous pharmaceutical compositions for the treatment of inflammatory disorders comprising an antiinflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier.
• [EN] 5-LIPOXYGENASE INHIBITORS
  申请人：——

  公开号：WO1991014674A2

  公开（公告）日：1991-10-03

  [EN] Hydroxyurea compounds comprising substituted and unsubstituted 1,2,3,4-tetrahydronaphthalene, indane, dihydrobenzofuran, 4H-2,3-dihydrobenzopyran, dihydrobenzothiophene, and indoline derivatives, pharmaceutical compositions containing said compounds, and their use as analgesics and 5-lipoxygenase pathway inhibitors.
  [FR] On décrit des composés d'hydroxyurée comprenant de l'indane, du dihydrobenzofuranne, du 4H-2,3-dihydrobenzopyranne, du dihydrobenzothiophène, des dérivés d'indole et du 1,2,3,4-tétrahydronaphtalène substitués et non substitués, des compositions pharmaceutiques contenant lesdits composés et leur utilisation comme analgésiques et inhibiteurs de voies d'accès de 5-lipoxygénase.